CereVasc is a clinical-stage medical device company based in Massachusetts developing the eShunt System, an investigational, patented endovascularly implantable cerebrospinal fluid shunt and delivery components. The eShunt employs a percutaneous transvenous-transdural approach intended to enable a minimally invasive treatment for communicating hydrocephalus. The company is currently conducting the STRIDE pivotal trial, a prospective, multi-center, randomized, controlled study comparing the eShunt System to the standard ventriculo-peritoneal (VP) shunt to evaluate safety and effectiveness. Data from STRIDE are intended to support a future FDA Premarket Approval (PMA) submission. CereVasc describes the eShunt as investigational and not yet approved for commercial sale. The company plans to use recent Series C proceeds to complete the pivotal trial, advance regulatory work, scale operations, and prepare for U.S. commercialization.

Total raised

$199M

Funding rounds

3

Latest round

Series C

Latest activity

Jun 2026